Skip to main content

Table 2 Associations between serial glycemic parameters over time and ICU mortality

From: Hyperglycemia and glucose variability are associated with worse survival in mechanically ventilated COVID-19 patients: the prospective Maastricht Intensive Care Covid Cohort

 

mean glucose

maximum glucose difference

Model 1: Crude

β

mmol/l

CI (95%)

mmol/l

β

mg/dl

CI (95%)

mg/dl

p-value

β

mmol/l

CI (95%)

mmol/l

β

mg/dl

CI (95%)

mg/dl

p-value

ICU-survivors

(reference)

-

-

  

-

-

-

  

-

Mortality

0.67

0.25; 1.10

12.1

4.5; 19.8

0.002

0.86

0.38; 1.34

15.4

6.84; 24.12

< 0.001

time * ICU non-survivors (slope)

-0.06

-0.08; -0.04

-1.08

-1.44; 0.72

< 0.001

-0.03

-0.05; -0.01

0.54

-0.9; -0,18

0.001

Model 2*: Adjusted

          

ICU-survivors

(reference)

-

-

-

-

-

-

-

-

-

-

Mortality

0.64

0.21; 1.07

11.5

3.8; 19.3

0.003

0.87

0.39; 1.35

15.7

7.02; 24.3

< 0.001

time * ICU non-survivors (slope)

-0.06

-0.08; -0.04

-1.1

-1.44; -0.72

< 0.001

-0.03

-0.05; -0.01

-0.54

0.9; 0.18

0.007

  1. β (95% CI) indicates the regression coefficient, or difference and slope over time of mean glucose (mmol/l and mg/dl) and maximum glucose (in mmol/l and mg/dl ) difference per day, respectively, for ICU non-survivors, with ICU survivors as reference. Model 1: Crude analysis. Model 2: adjusted for age, sex, body mass index (BMI) and APACHE II score, chronic kidney, pulmonary and liver diseases, and cardiovascular risk factors
  2. CI: Confidence Interval, ICU: Intensive Care Unit;
  3. *Data on BMI (n = 3) and cardiovascular risk factors (n = 3) were missing; hence model 2 included 226